An Exploratory Study on the Antibiotic Potentiation Activity of Riboflavin Against Biofilm‐Forming Multidrug‐Resistant Salmonella and Shigella Clinical Isolates
- 1West African Centre for Cell Biology of Infectious Pathogens Department of Biochemistry Cell and Molecular Biology University of Ghana Accra Ghana ug.edu.gh
- 2AMR Research Group West African Centre for Cell Biology of Infectious Pathogens College of Basic and Applied Science University of Ghana Accra Ghana ug.edu.gh
Abstract
Shigella and Salmonella strains have been implicated in neonatal sepsis, food poisoning, and bacteremia. Their increasing resistance to antibiotics has undermined treatment options, constituting a public health crisis. In addition, the scarcity of new antibiotics contributes to multidrug‐resistance (MDR). Hence, there is a need to potentiate antibiotics to mitigate MDR. This study assessed riboflavin′s activity to potentiate antibiotics against biofilm‐forming MDR Shigella and Salmonella spp. Disk diffusion, microbroth‐dilution, chequerboard, and time‐kill assays were used to determine resistance profiles and riboflavin‐antibiotic activity. Biofilm‐formation and bacterial viability (after riboflavin–antibiotic challenge) were determined with crystal‐violet and macrophage infection assays, respectively. Strains exhibited > 80% resistance to fluoroquinolones and carbapenems, with 160–640 μg/mL MIC ranges. At 40–80 μg/mL riboflavin, there was a twofold reduction in bacterial survival, with meropenem–riboflavin exhibiting significant reduction. Meropenem + riboflavin was highly synergistic in four MDR isolates (an FIC of 0.075). Biofilm formation was altered (from strong to weak phenotype) with 40 μg/mL riboflavin–antibiotic treatment. There was a 40%–70% reduction in bacterial survival in THP‐1 cells treated with meropenem–riboflavin after 3 h, and complete clearance between 24 and 48 hpi. Overall, the study showed that riboflavin potentiated fluoroquinolones, meropenem, and enhanced clearance in THP‐1 assays.
Related
- Modulation of riboflavin biosynthesis enzymes in non-typhoidal Salmonella isolates differentially impacts human MAIT cell activation
- Early best available antibiotic therapy for multidrug-resistant gram-negative bloodstream infections: a target trial emulation
- Ecology and epidemiology of multidrug resistance Salmonella in fruit Bats and shared water sources in Bangladesh
- Salmonella aortitis without surgery or fluoroquinolones: Complete resolution with sequential antibiotic therapy
- Retail fish markets in Bangladesh are hidden hotspots of multidrug resistant Salmonella providing critical One Health insights
BibTeX
@article{isawumi2026exploratory,
title = {{An Exploratory Study on the Antibiotic Potentiation Activity of Riboflavin Against Biofilm‐Forming Multidrug‐Resistant Salmonella and Shigella Clinical Isolates}},
author = {Abiola Isawumi and Gloria Kutorkor Addo and Elizabeth W. Bugase and Eunice Ampadubea Ayerakwa and Molly Kukua Abban},
journal = {International Journal of Microbiology},
year = {2026},
month = oct,
doi = {10.1155/ijm/1772416},
url = {https://doi.org/10.1155/ijm/1772416},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - An Exploratory Study on the Antibiotic Potentiation Activity of Riboflavin Against Biofilm‐Forming Multidrug‐Resistant Salmonella and Shigella Clinical Isolates
AU - Abiola Isawumi
AU - Gloria Kutorkor Addo
AU - Elizabeth W. Bugase
AU - Eunice Ampadubea Ayerakwa
AU - Molly Kukua Abban
PY - 2026
DA - 2026/10/29
JO - International Journal of Microbiology
DO - 10.1155/ijm/1772416
UR - https://doi.org/10.1155/ijm/1772416
AB - Shigella and Salmonella strains have been implicated in neonatal sepsis, food poisoning, and bacteremia. Their increasing resistance to antibiotics has undermined treatment options, constituting a public health crisis. In addition, the scarcity of new antibiotics contributes to multidrug‐resistance (MDR). Hence, there is a need to potentiate antibiotics to mitigate MDR. This study assessed riboflavin′s activity to potentiate antibiotics against biofilm‐forming MDR Shigella and Salmonella spp. Disk diffusion, microbroth‐dilution, chequerboard, and time‐kill assays were used to determine resistance profiles and riboflavin‐antibiotic activity. Biofilm‐formation and bacterial viability (after riboflavin–antibiotic challenge) were determined with crystal‐violet and macrophage infection assays, respectively. Strains exhibited > 80% resistance to fluoroquinolones and carbapenems, with 160–640 μg/mL MIC ranges. At 40–80 μg/mL riboflavin, there was a twofold reduction in bacterial survival, with meropenem–riboflavin exhibiting significant reduction. Meropenem + riboflavin was highly synergistic in four MDR isolates (an FIC of 0.075). Biofilm formation was altered (from strong to weak phenotype) with 40 μg/mL riboflavin–antibiotic treatment. There was a 40%–70% reduction in bacterial survival in THP‐1 cells treated with meropenem–riboflavin after 3 h, and complete clearance between 24 and 48 hpi. Overall, the study showed that riboflavin potentiated fluoroquinolones, meropenem, and enhanced clearance in THP‐1 assays.
SN - 1687-918X
SN - 1687-9198
ER -